CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H3003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
1.84 ^USD	-35.21%		-23.97%	-97.10%

26/06	Top Midday Decliners	MT
26/06	Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures	MT

CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 16, 2024 at 02:31 am IST

CNS Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 3.54 million compared to USD 4.93 million a year ago. Basic loss per share from continuing operations was USD 20.5 compared to USD 129.5 a year ago.

Diluted loss per share from continuing operations was USD 20.5 compared to USD 129.5 a year ago.

Latest news about CNS Pharmaceuticals, Inc.

Top Midday Decliners	27/06	MT
Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures	26/06	MT
CNS Pharmaceuticals, Inc. announced a financing transaction	26/06	CI
CNS Pharmaceuticals, Inc. announced that it expects to receive $1.3725 million in funding	14/06	CI
Sector Update: Health Care Stocks Advance Late Afternoon	11/06	MT
Top Midday Decliners	10/06	MT
CNS Pharmaceuticals Files Registration Statement for $9.2 Million Share, Warrant Offering -- Shares Fall	10/06	MT
CNS Pharmaceuticals Schedules 1-For-50 Reverse Stock Split This Week	03/06	MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
CNS Pharmaceuticals, Inc. Announces Committee Changes	04/05	CI
Transcript : CNS Pharmaceuticals, Inc. - Shareholder/Analyst Call	01/05
Transcript : CNS Pharmaceuticals, Inc. - Special Call	23/04
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees	28/02	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	30/01	MT
CNS Pharmaceuticals Prices $4 Million Offering; Shares Fall Pre-Bell	30/01	MT
CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors	18/01	CI
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	17/01	CI
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	18/12	CI
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	22/11	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Transcript : CNS Pharmaceuticals, Inc. - Pre Recorded Special Call	18/23/18
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland	11/23/11	CI
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme	07/23/07	CI
CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy	14/23/14	CI

Chart CNS Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
CNS PHARMACEUTICALS, INC.	-97.10%	436K
MODERNA, INC.	+23.13%	46.93B
LONZA GROUP AG	+37.35%	39.08B
IQVIA HOLDINGS INC.	-8.73%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	31.01B
CELLTRION, INC.	-12.26%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.57%	25.88B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+32.23%	12.53B
BIO-TECHNE CORPORATION	-6.56%	11.36B

Other Biotechnology & Medical Research